Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis)
- PMID: 16998756
- DOI: 10.1007/s00415-006-5010-2
Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis)
Erratum in
- J Neurol. 2008 Feb;255(2):308
Abstract
Polymyositis, dermatomyositis, and inclusion body myositis are idiopathic inflammatory myopathies of unknown etiology with autoimmune pathogenesis. For choosing an individual and efficient therapy, diagnostic assignment is an important factor. Therapeutic options in dermatomyositis and polymyositis include corticosteroids and immunosuppressives. Intravenous immunoglobulins are only needed in special cases. In inclusion body myositis, corticosteroids and immunosuppressives are not successful. At the moment intravenous immunoglobulins are the only therapeutic possibility.
Similar articles
-
[Current therapy for polymyositis and dermatomyositis].Rev Med Interne. 2008 Jun;29 Spec No 2:9-14. Rev Med Interne. 2008. PMID: 18927983 Review. French.
-
Treatment of idiopathic inflammatory myopathies.Curr Opin Neurol. 2003 Oct;16(5):569-75. doi: 10.1097/01.wco.0000093099.34793.40. Curr Opin Neurol. 2003. PMID: 14501840 Review.
-
Inflammatory myopathies: evaluation and management.Semin Neurol. 2008 Apr;28(2):241-9. doi: 10.1055/s-2008-1062267. Semin Neurol. 2008. PMID: 18351525 Review.
-
Treatment of polymyositis and dermatomyositis.Br J Hosp Med. 1994 Nov 2-15;52(9):463-8. Br J Hosp Med. 1994. PMID: 7874361 Review.
-
[Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S48-50. Ann Med Interne (Paris). 2000. PMID: 10896990 French.
Cited by
-
Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.Curr Rheumatol Rep. 2011 Jun;13(3):192-8. doi: 10.1007/s11926-011-0171-0. Curr Rheumatol Rep. 2011. PMID: 21503696 Review.
-
Crocin restores the balance of Th1/Th2 immune cell response in ConA-treated human lymphocytes.Pharmacol Rep. 2022 Jun;74(3):513-522. doi: 10.1007/s43440-022-00362-3. Epub 2022 Mar 16. Pharmacol Rep. 2022. PMID: 35294736
-
Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?Rheumatol Int. 2012 Feb;32(2):469-72. doi: 10.1007/s00296-009-1290-z. Epub 2010 Jan 1. Rheumatol Int. 2012. PMID: 20044785
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources